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Abstract: Older adults (≥65 years) are at elevated risk of influenza-related morbidity and mortality.
Many developed countries do not achieve the World Health Organization influenza immunization
target of 75% in people ≥65 years. We aimed to determine whether a brief pharmacy phone call could
increase vaccine uptake of standard and enhanced influenza. Twenty-eight community pharmacists
across Canada performed a telephone consultation with 643 older adults whose primary care records
indicated that they had not received their influenza vaccination from their usual practitioner. Of these
643 adults, 169 (26.3%) had been vaccinated in another setting. Of the remaining 474, 313 (66%) agreed
to receive the vaccine. Of those who refused vaccination, 69 provided a rationale for not wanting it,
including that the flu shot “causes the flu” (n = 25), “doesn’t work” (n = 25), “is too painful” (n = 10),
and other (n = 10). Overall, of the 643 individuals who had not received their vaccination from their
usual health care provider in the first wave of vaccinations, 75.4% (n = 485) ultimately received their
vaccination in the 2019–2020 season. This highlights the important role of the community pharmacist
in achieving the World Health Organization (WHO) targets for vaccination.
Keywords: influenza; vaccine; immunisation; vaccine hesitancy
1. Introduction
The National Advisory on Immunization (NACI) estimates that there are an average
of 12,200 hospitalizations related to influenza and approximately 3,500 deaths attributable
to influenza annually in Canada [1]. Public Health England estimates that, on average,
17,000 people have died of influenza in England alone annually since 2014. In the USA, the
Center for Disease Control and Prevention (CDC) has estimated the numbers of influenza
cases ranged from 9–45 million a year and deaths from 12,000 to 61,000 in the same time
frame. The majority (~90%) of influenza-related deaths in the 2018–2019 flu season in the
US were in older adults (>65 years) and, among older survivors, it was determined that
13% will experience catastrophic disability and face the prospect of loss of independence
and quality of life [2]. As such, individuals ≥65 years of age form the optimal age group to
target for preventive measures, with demonstrable personal and health economic benefits
by achieving reductions in cases in this vulnerable population.
Annual vaccination is arguably the most effective public health strategy for preventing
influenza. National immunization programs across the world prioritise achieving optimal
influenza vaccination coverage in older and vulnerable adults [1,3,4]. In this connection,
the World Health Organization (WHO) recommends that 75% of those 65 years of age and
older receive an influenza vaccine [5]. Many countries set slightly different targets for this
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age group, such as Canada, who has an 80% influenza immunization target for this age
group [6]. In recent years, however, the United States, Canada and the United Kingdom
have not achieved these targets [7–12].
The reasons for failure to attain benchmark influenza vaccine coverage are complex
and multifactorial. Proposed explanations include a perceived lack of salience, lack of
access to vaccines, a belief in common influenza vaccine myths such as the belief that
influenza is not a serious health concern, or a belief that the influenza vaccine is ineffective
and/or causes the disease [13–15]. Furthermore, there remain unprecedented additional
barriers to immunization that are posed due to the pandemic co-circulation of SARS-CoV-
2 and influenza in the upcoming 2020–2021 influenza season in the Northern Hemisphere.
Physical distancing and shielding of high-risk individuals may reduce the number of
individuals that present for routine vaccinations including seasonal influenza. New ways
of working in primary and secondary care, including widespread reliance on telemedicine,
may reduce capacity for in-person vaccination clinics and may leave large numbers of
people without usual access to vaccinations. With the risk of a second wave of COVID-19,
the potential for a dual viral outbreak (influenza and coronavirus) could have devastating
results in vulnerable populations such as those ≥65 years of age [16,17].
Over and above these obstacles to optimal influenza vaccine coverage in older adults is
evidence of an approximate 50% decrease in effectiveness of standard, egg-derived vaccines
in the older age group compared to younger adults [1]. This is thought to be largely due
to immunosenescence, an age-related functional decline of innate and acquired immune
systems that results in suboptimal humoral responses to vaccination [18]. Two enhanced
vaccine options, however, have been introduced to increase immune response and improve
outcomes in older adults. The high-dose trivalent influenza vaccine (TIV-HD) has been
shown to reduce the number of influenza cases and hospitalization due to pneumonia
in older adults compared to standard dose influenza vaccine (TIV) [19–21]. Furthermore,
influenza vaccine with MF59 adjuvant (TIV-adj) has been shown to reduce the number of
influenza cases, hospitalization due to pneumonia, and fewer cases of acute coronary and
cerebrovascular event hospitalization in older adults compared to standard dose influenza
vaccine (TIV) [22–28].
Pharmacists and their pharmacy teams are a growing resource that can support pri-
mary care in a wide variety of roles, and these professionals have the confidence of the older
adult population [29,30]. Their roles in medications review, chronic disease management,
administering immunizations, and providing educational engagement have demonstrated
improved clinical outcomes in a range of conditions [31–34]. We hypothesised that engage-
ment between pharmacists and individuals at high risk of severe influenza disease would
help to increase influenza vaccine coverage in this population, ultimately helping to achieve
the 75% benchmark vaccine coverage established by the WHO. Here, we present the out-
comes of a quality improvement program aimed at increasing influenza immunization in
individuals ≥65 years of age during the 2019–2020 influenza season in three Canadian
provinces by facilitating conversations about influenza vaccination with consumer-facing
pharmacy staff. A process evaluation of the intervention was also undertaken to determine
whether a greater knowledge of available interventions would influence patient choices
when considering enhanced influenza vaccine options.
2. Methods
Pharmacies in the Canadian provinces of Alberta, British Columbia, and Saskatchewan
were approached for participation in a quality improvement program. These pharmacies
were all part of one pharmacy chain with a pharmacy director who actively encouraged
participation in the program.
A telephone script was created to guide a brief (target 1–3 min) and effective dis-
cussion on influenza vaccination between pharmacy staff and unvaccinated individuals
≥65 years of age. An accompanying patient education package for use in these discussions
was developed in conjunction with health care practitioners, pharmacists and potential
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patients (Supplementary File A). The community pharmacists did not receive any incentive
beyond the usual government reimbursement for the administration of the flu vaccines for
participation in this program.
2.1. Participants
The participants were selected through printing a report of individuals ≥65 years who
had not received an influenza vaccine dose for the 2019–2020 season from the pharmacy dis-
pensing software. Pharmacists, pharmacy assistants, or pharmacy technicians telephoned
individuals in this report. The telephone call was designed to take 1 to 3 min, and the
intervention was designed to be integrated into the routine practice of the pharmacy. The
primary outcome in this quality improvement programme was for those contacted to have
an appointment for influenza vaccine administration arranged by the end of the telephone
consultation. If a patient declined to receive the influenza vaccine, they were asked for
their reason(s). The pharmacy team was provided with patient education information
(Supplemental File A) to address common reasons for vaccine hesitancy to try and improve
vaccine uptake in this age group.
As a secondary process evaluation outcome, we evaluated the impact of information
contained in these scripted conversations concerning enhanced vaccine options for those
≥65 years of age. These vaccines are not reimbursed as part of the routine influenza
immunization program in Canada when administered in the pharmacy and were subject
to individual payment. We provided supporting information for pharmacists aimed at
informing patients about enhanced vaccine options and asked participants if they would
like to receive one of these enhanced vaccines.
2.2. Statistical Analysis
This is a secondary analysis of a quality improvement programme. Therefore, no
formal statistical calculations (such as a power calculation) were performed. Rather, de-
scriptive statistics on the cohort of individuals identified as part of the quality improvement
program are presented.
2.3. Patient and Public Involvement
The concept of pharmacist involvement in order to improve adherence to pharmaco-
logical therapies has been evaluated with older adults with long-term diseases in several
different disease areas by this group. A focus group of older adults contemplating vac-
cination was interviewed regarding their perception of a pharmacist-based telephone
consultation. The population were welcoming of engagement with these health care profes-
sionals with regard to delivery of medical interventions, as long as they were not expected
to make new clinical diagnoses.
The telephone script was developed in conjunction with a patient focus group of
appropriate age to receive the intervention. The primary goal of this was to evaluate the
effectiveness and acceptability of the telephone conversation in addition to the ability to
comprehend of the language used.
3. Results
Overall, this program was implemented in 28 pharmacies in the Canadian provinces
of Alberta, British Columbia, and Saskatchewan. Six hundred and forty-three individuals
were identified, all of whom were at risk for severe influenza disease based on their age
(≥65 years) and the lack of a pharmacy record of influenza immunization at the time the
telephone call was placed. Individuals were contacted predominantly at the “tail end” of
the vaccination season in order to target those who did not respond to initial invitations
from their primary care physicians, from 7 October 2019 until 26 January 2020 (Figure 1).
The telephone script is presented in Supplementary File A. Our process evaluation targeted
most older adults during
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Figure 1. Time in the flu season when individuals were contacted. Note: the usual vaccination season
commences in Mid-September in Canada. These individuals were contacted later in the flu-season
in order to address vaccine hesitancy among those that had not responded to their initial primary
care invitations.
December and January and thus, by definition, captures individuals who had missed
or chosen not to participate in the initial annual influenza immunization clinics.
3.1. Evaluation of Primary Outcome
In this population of 643 individuals who did not have a documented influenza
vaccine from their primary provider, 169 (26.3%) had been vaccinated in another setting.
Of the remaining 474, 316 (67%) agreed to receive the vaccine by the end of the telephone
consultation (Figure 2). Thus, in total, 485 (75.4%) people received their influenza vaccine
by the end of this intervention. As such, this quality improvement project demonstrated
its primary target of achieving the WHO recommended 75% influenza vaccine uptake in
older adults who had not been vaccinated by their usual care provider in the first wave.
3.2. Reason for Declining the Influenza Vaccine and Efficacy of Correcting Myth
One hundred and sixty-one older adults who had not received an influenza vaccine
from another healthcare professional initially declined to receive the vaccine. Of the
161 who declined the vaccine, 69 gave a reason (Table 1). The pharmacy team was able to
address the reason for not receiving the vaccine for 31 of these individuals, people with a
simple information script.
Table 1. Reason for not wanting to receive the influenza vaccine.
Reason Number of Older Adults(% of Patients Providing Reason)
“Flu shot causes the flu” 25 (36%)
“Flu shot doesn’t work” 24 (35%)
“Flu shot is too painful” 10 (14%)
“I would rather wait until the flu comes into the community” 6 (9%)
“I had the flu shot last year; I don’t need it again” 4 (6%)
























Figure 2. Patient pathway in the quality improvement project.
3.3. Interest in Receiving an Enhanced Influenza Vaccine
All older adults who agreed to receive the influenza vaccine were asked if they
would like to receive the unadjuvanted quadrivalent vaccine that was part of the routine
influenza vaccine at no cost or an enhanced vaccine that they would have purchase. By
the end of the telephone conversation, 162 (52%) of participants had made a definite
choice. Of these, 64 (39.5%) selected the enhanced vaccine at additional personal cost, and
a further 40 individuals were amenable to receiving more details during their consultation
at the pharmacy.
4. Discussion
Findings from this project support the utility of a simple pharmacy-led telephone en-
gagement tool to increase vaccination uptake in older adults, thereby helping to achieve the
World Health Organization’s target of 75% vaccination against influenza in this age group.
There are several factors affecting influenza vaccine uptake in older adults. Even
with the benefits of influenza immunization being clearly demonstrated, some reluctant
to receive the vaccine [35]. Barriers to influenza vaccination include a lack of perceived
severity of influenza nd concerns about the effectiveness of vaccines [35]. Some older
adults may also be fearful of adverse effects, real or perceived, associated with the in-
fluenza vaccine [35]. Population reviews found that patients who are part of a visible
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minority group have lower household income, poor physical activity, lack of access to
healthcare resources, and better overall health were more likely to not receive an influenza
vaccine [36–38]. There is observational data demonstrating that having severe functional
limitations (severe frailty) increases the risk of death by 13-fold but decreases the likeli-
hood of influenza immunization [39]. Finally, a lack of awareness of the importance of
vaccination and the benefits of self-care, or a simple failure to prioritise self-care may also
be contributing factors to patients who do not see their healthcare professional during the
immunization season failing to receive the vaccine.
This short pharmacy quality improvement evaluation supports the notion that the
majority of older adults are receptive to receiving the influenza vaccine after a short
telephone conversation. Indeed, of individuals who had not received influenza vaccination,
two thirds were easily persuaded to receive this potentially lifesaving intervention. This
suggests that a primary reason for not receiving the influenza vaccine is not vaccine
hesitancy but rather simple inertia—failing to prioritise an individual’s own health. Vaccine
hesitancy was an issue in a small number of older adults. The most common reasons were
the beliefs that the influenza vaccine is not effective or that it causes influenza. Some
older adults were receptive to hear a short pre-written script to address their reason for
not wanting to receive the influenza vaccine; however, education regarding the myth was
only effective in 3 (4.3% of those who provided a reason for declining the vaccine). The
pharmacists were not trained on how to deliver the script per-se, which may also have
affected the quality of the intervention in terms of addressing patients’ hesitancy. Further
research in this connection is warranted.
A lack of belief in the efficacy of the vaccine was cited by several older adults as a rea-
son for vaccine hesitancy. Interestingly, when presented with information about enhanced
influenza vaccine options for their age group, approximately two fifths of individuals
opted for the enhanced vaccine at additional personal cost. In some regions of the world,
we note enhanced influenza vaccines are the standard of care for older adults [40]. During
the 2019–2020 influenza vaccine season, enhanced vaccines administered by pharmacists to
outpatients in Canada were not part of the routine influenza immunization program. Our
data demonstrates that a significant portion of older adults are interested in receiving the
enhanced influenza vaccine or at least learning more. We believe that older adults should
be provided the option of an enhanced influenza vaccine and be allowed to decide which
influenza vaccine option is suitable for their circumstance.
The influenza season in the Northern Hemisphere typically starts in November and
ends in March [1]. Most influenza immunization programs, clinics, and vaccine promotion
are targeted in October and November to immunise people before the onset of the influenza
season. Our process evaluation targeted most older adults during December and January
and thus, by definition, captures individuals who had missed or chosen not to participate
in the initial annual influenza immunization clinics. This method targets ‘’salvage vaccina-
tions” who were missed through other influenza public health initiatives. Therefore, we
are exploring patients who, although eligible for treatment, have not engaged with the
immunization program.
Pharmacist influenza immunization has been studied broadly. Pharmacist immuniza-
tion has been found to increase vaccine uptake [31,41,42] and is a cost-effective consultation
that leads to improved clinical outcomes [43]. Patients found that the pharmacist-based
immunization was a positive experience [44], accessible with high patient favourability [30].
Our intervention contributes to this literature by exploring and demonstrating benefits
in older adults that do not receive their vaccine in the “first round” and therefore are,
almost by definition, vaccine resistant. The finding that the majority of these older adults
are receptive to receiving influenza immunization when contacted by their pharmacy
is encouraging. This is particularly important in the coming 2020–2021 “twindemic” of
seasonal influenza with a second wave of COVID-19.
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5. Limitations
There are several limitations to our process evaluation. The intervention was con-
ducted via telephone and captures as its endpoint scheduled commitment to receive the
vaccine and not observed vaccination per se. It also included a small subset of provinces
and pharmacies in Canada. We were not able to capture non-responsiveness, or the number
of people targeted versus who we connected with. This needs to be addressed in a prospec-
tive cluster randomised study. With regards to those receiving enhanced vaccination with
either quadrivalent or adjuvant vaccination, the longer-term outcomes are not recorded.
Studies with the enhanced vaccines in older adults have been shown to reduce influenza
cases, hospitalizations due to pneumonia, and fewer cases of acute cases of acute coronary
and cerebrovascular event hospitalizations [19,22–24].
Although there are several limitations, there are several strengths. This program is a
simple and short intervention that can easily implemented into the average pharmacy. With
a small-time commitment, pharmacists were able to ensure a large portion of older adults
were immunised against influenza; added to ambient vaccination, levels this program
achieved the WHO influenza vaccine coverage benchmark.
6. Conclusions
A short and practical pharmacy intervention in three provinces in Canada was able
to reach the WHO 75% influenza immunization target for older adults. A small amount
of time and cost could increase influenza immunization in this high-priority population.
With the immunization issues during the COVID-19 pandemic, this program may be able
to ensure that individuals are protected while COVID-19 is circulating in the community.
This process evaluation demonstrated a significant impact on influenza immunization rates
in older adults as well as impact of information about enhanced vaccines. We believe this
proof of concept justifies further evaluations in different regions of the world and strongly
supports the role of the pharmacy in influenza immunization in older adults.
Supplementary Materials: The following are available online at https://www.mdpi.com/2076-393
X/9/4/312/s1, File A: Strategy and flow chart of the pharmacist intervention.
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